{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:57:11Z","timestamp":1765976231986,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00280-018-3725-2","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T05:23:30Z","timestamp":1542345810000},"page":"289-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors"],"prefix":"10.1007","volume":"83","author":[{"given":"Masanori","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Amagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Natsume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Quadt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Shirao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-9145","authenticated-orcid":false,"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"3725_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1073\/pnas.0408864102","volume":"102","author":"S Kang","year":"2005","unstructured":"Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102:802\u2013807","journal-title":"Proc Natl Acad Sci USA"},{"key":"3725_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt\/PKB by the rictormTOR complex. Science 307:1098\u20131101","journal-title":"Science"},{"key":"3725_CR3","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1016\/j.canlet.2005.11.042","volume":"241","author":"L Chow","year":"2006","unstructured":"Chow L, Baker S (2006) PTEN function in normal and neoplastic growth. Cancer Lett 241:9817\u20139824","journal-title":"Cancer Lett"},{"key":"3725_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1440-1789.2004.00600.x","volume":"25","author":"H Ohgaki","year":"2005","unstructured":"Ohgaki H (2005) Genetic pathways to glioblastomas. Neuropathology 25:1\u20137","journal-title":"Neuropathology"},{"key":"3725_CR5","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-05-1278","volume":"66","author":"Z Zeng","year":"2006","unstructured":"Zeng Z, Samudio IJ, Zhang W et al (2006) Simultaneous inhibition of PDK1\/Akt and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66:3737\u20133746","journal-title":"Cancer Res"},{"key":"3725_CR6","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","volume":"7","author":"SM Maira","year":"2008","unstructured":"Maira SM, Stauffer F, Brueggen J et al (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851\u20131863","journal-title":"Mol Cancer Ther"},{"key":"3725_CR7","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1200\/jco.2010.28.15_suppl.3005","volume":"28","author":"H Burris","year":"2010","unstructured":"Burris H, Rodon J, Sharma S et al (2010) First-in-human phase I study of the oral dual PI3K and mTORC1\/2 inhibitor BEZ235 in patients with advanced solid tumors. J Clin Oncol 28:3005","journal-title":"J Clin Oncol"},{"key":"3725_CR8","doi-asserted-by":"crossref","unstructured":"Rodon J, Infante J, Burris H, Tabernero JM (2010) A dose escalation study with a Special Drug Delivery System (SDS) of BEZ235, a novel dual PI3K\/mTOR inhibitor, in patients with metastatic\/advanced solid tumors. San Antonio Symposium. San Antonio, USA","DOI":"10.1158\/0008-5472.SABCS10-P6-15-07"},{"key":"3725_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-018-3610-z","volume":"82","author":"J Rodon","year":"2018","unstructured":"Rodon J, P\u00e9rez\u2013Fidalgo A, Krop IE et al (2018) Phase I\/Ib dose escalation and expansion study of BEZ235, a dual PI3K\/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol 82:285\u2013298","journal-title":"Cancer Chemother Pharmacol"},{"key":"3725_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0959-8049(12)71083-3","volume":"48","author":"A Rodon","year":"2012","unstructured":"Rodon A, Burris HA, Schellens JHM et al (2012) Phase I dose-escalation study of the oral dual mTOR\/PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet formulation, in patients with advanced solid tumors. Eur J Cancer 48:Suppl 6:112","journal-title":"Eur J Cancer"},{"key":"3725_CR11","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1200\/jco.2011.29.15_suppl.3066","volume":"29","author":"JD Peyton","year":"2011","unstructured":"Peyton JD, Rodon Ahnert J, Burris H et al (2011) A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol 29:3066","journal-title":"J Clin Oncol"},{"key":"3725_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10637-015-0218-6","volume":"33","author":"JC Bendell","year":"2015","unstructured":"Bendell JC, Kurkjian C, Infante JR et al (2015) A phase I study of the sachet formulation of the oral dual PI3K\/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs 33:463\u2013471","journal-title":"Invest New Drugs"},{"key":"3725_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1634\/theoncologist.2016-0145","volume":"21","author":"MI Carlo","year":"2016","unstructured":"Carlo MI, Molina AM, Lakhman Y (2016) A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) andMammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. Oncologist 21:787\u2013788","journal-title":"Oncologist"},{"key":"3725_CR14","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-14-1998","volume":"21","author":"TK Owonikoko","year":"2015","unstructured":"Owonikoko TK, Ramalingam SS, Miller DL et al (2015) A translational, pharmacodynamic, and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer. Clin Cancer Res 21:1859\u20131868","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3725-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:19:04Z","timestamp":1573845544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3725-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3725"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3725-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"13 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Taro Amagasaki, Kazuto Natsume, Hiromi Takeuchi, and Cornelia Quadt are employees of Novartis. Hironobu Minami has received research funding from Novartis KK. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}